- Home
- PSNYW vs PALI Comparison
PSNYW vs PALI Comparison
Compare PSNYW & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | PALI |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | Sweden | United States |
| Employees | 2547 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 240.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | PALI |
|---|---|---|
| Price | $3.51 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 5.3K | ★ 4.1M |
| Earning Date | 03-06-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $0.14 | $0.55 |
| 52 Week High | $7.50 | $2.64 |
Technical Indicators
Market Signals| Indicator | PSNYW | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 67.26 |
| Support Level | $3.39 | $1.57 |
| Resistance Level | $4.60 | $2.45 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.15 | 0.06 |
| Stochastic Oscillator | 20.30 | 88.20 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.